Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

With a mean weight loss of 16.6%1, Wegovy® pill demonstrates best-in-class weight-loss efficacy and is the first oral GLP-1 treatment recommended by CHMP for weight management in the EU. CHMP recommends Wegovy® pill for approval to reduce excess body weight and maintain long-term weight reduction.